What happened with HRMY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Harmony Biosciences Holdings relies on WAKIX (pitolisant), its only approved product, for all revenue. The drug treats excessive daytime sleepiness and cataplexy in adults with narcolepsy, and excessive daytime sleepiness in children with narcolepsy. Harmony sells it to specialty distributors that supply patients. Its product sales are concentrated entirely in three customers: Caremark LLC, Accredo Health Group, Inc. and PANTHERx Specialty Pharmacy LLC. Demand depends heavily on physicians prescribing WAKIX and government and private insurers covering and reimbursing treatment.
Harmony licenses exclusive U.S. commercialization rights from Bioprojet and pays it royalties tied to sales. It contracts out manufacturing, storage, distribution and testing rather than operating those facilities itself, so sales also depend on outside suppliers keeping the drug available.
Harmony is developing additional uses and formulations of pitolisant and other drug candidates for rare neurological diseases. These are development programs, not additional revenue sources. It cannot market WAKIX for unapproved uses, and its pitolisant development work requires Bioprojet’s consent under the licensing agreements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Harmony’s results hinge on WAKIX demand and its licensed rights and royalty obligations to Bioprojet, with Centessa—absent from this list—another potential narcolepsy rival developing orexin-2 receptor agonists.
Jazz Pharmaceuticals sells Xywav and Xyrem to narcolepsy patients who may also receive Harmony’s WAKIX, so treatment choices and insurers’ coverage decisions matter to both businesses. Watch changes in coverage and use of Xywav and Xyrem, not just Jazz’s overall drug sales.
Alkermes Inc. plc competes for narcolepsy treatment sales with Harmony’s WAKIX through its acquired Lumryz business. Its development of orexin-2 receptor agonists adds a potential future challenge, making both Lumryz sales and progress on those candidates worth watching.
Axsome Therapeutics, Inc sells SUNOSI for excessive daytime sleepiness in narcolepsy, competing with Harmony’s WAKIX for those patients, though SUNOSI does not treat cataplexy. Watch SUNOSI’s narcolepsy business rather than its sleep-apnea use, along with AXS-12’s development as a potential additional rival.
Takeda Pharmaceutical’s investigational narcolepsy medicines could challenge WAKIX, which generates all of Harmony’s revenue. For this tie, watch progress on Takeda’s orexin-2 receptor agonists rather than sales across its worldwide prescription-drug business.
Amneal Pharmaceuticals, Inc. sells generic sodium oxybate for narcolepsy, competing with Harmony’s WAKIX and potentially influencing which treatments insurers prefer to cover. Watch coverage preferences for this generic, since Harmony’s net WAKIX revenue reflects government and commercial rebates as well as other discounts.
Alkermes Inc. plc earningsALKS
Alkermes sells Lumryz to people with narcolepsy, and its report will show whether the drug is drawing patients who might otherwise use Harmony Biosciences’ WAKIX.
Look for Alkermes’ update on Lumryz sales and whether it points to demand from people with narcolepsy. Growing sales would show that this competing treatment is expanding; weak sales would suggest less pressure from Lumryz, but would not establish that WAKIX is gaining patients. The conclusion for Harmony is whether another narcolepsy treatment is drawing patients from the same pool.
Fed Interest Rate Decision
Harmony Biosciences’ Fed rate decision matters because its $165 million of debt carries interest tied to Term SOFR or a base rate, so policy rates can change what the company pays to borrow.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher-than-expected policy rates can lift the rates tied to Harmony Biosciences’ debt, increasing interest costs and leaving less cash for business development, growth or debt repayment.
If it comes in below expectations
Lower-than-expected policy rates can ease the rates tied to Harmony Biosciences’ debt, reducing interest costs and leaving more cash available for business development, growth or debt repayment.
Harmony Biosciences Holdings, Inc. earningsThis company
Harmony Biosciences relies entirely on WAKIX, and this report will show how much growth from patients and shipments remains after discounts and royalties.
Read WAKIX net product revenue alongside patient numbers, shipments and cost of product sales. Revenue rising with patients and shipments, without a marked increase in costs as a share of revenue, would show that added demand is supporting profit; if patients or shipments grow but net revenue does not, or costs take a larger share, discounts, rebates or higher royalties are absorbing more of the gain. The takeaway is whether WAKIX growth is adding revenue and profit that Harmony can retain.
Amneal Pharmaceuticals, Inc. earningsAMRX
Amneal sells generic sodium oxybate for narcolepsy, and its report may show whether insurers favor a lower-cost treatment that could put pressure on Harmony Biosciences’ WAKIX rebates and discounts.
Watch Amneal’s comments on demand for generic sodium oxybate and insurers’ coverage preferences, and read them alongside Harmony’s WAKIX net product revenue, which reflects rebates and other discounts. Stronger demand and a preference for lower-cost drugs, together with pressure on Harmony’s net revenue, would suggest that cheaper alternatives may be increasing discount pressure on WAKIX; without those signs, the evidence for that pressure is weaker, but WAKIX coverage or pricing is not confirmed. The takeaway is whether lower-cost competition may be squeezing the revenue Harmony keeps from WAKIX.
